BRITISH AMERICAN TOBACCO (BATS.L)

Key Updates

British American Tobacco has advanced +2.14% to £4,524 since the May 6 report, extending the recovery that began in late April. The stock now trades +7.36% YTD, marking a significant reversal from the negative territory observed in mid-April. This update focuses on competitive dynamics in the reduced-risk product segment, where industry leader Philip Morris continues to dominate while simultaneously facing regulatory headwinds on Zyn nicotine pouches. The news cycle reveals both opportunities and threats for BAT's Velo brand positioning.

Current Trend

BATS.L has demonstrated consistent upward momentum across all timeframes: +3.31% (1d), +5.06% (5d), +3.98% (1m), +6.60% (6m), and +7.36% YTD. The stock has now posted three consecutive positive reports since bottoming at £4,172 on April 14, recovering +8.44% over the past month. This recovery has established £4,200-£4,300 as a support zone, while the stock is testing new resistance near £4,550. The sustained uptrend across multiple timeframes indicates strengthening investor confidence, with the stock trading at its highest level since the previous analysis cycle began.

Investment Thesis

The investment thesis centers on BAT's transition to reduced-risk products while maintaining cash generation from traditional combustibles. The company benefits from industry-wide pricing power, demonstrated by Altria's ability to exceed sales expectations despite consumer trade-down to discount brands. BAT's Velo nicotine pouch brand is positioned to capture market share as Philip Morris faces FDA delays on new Zyn versions and competitive pressure. The thesis assumes that combustible cigarettes will remain profitable for the foreseeable future, as evidenced by PMI's projection that traditional products will still generate 51% of revenue by 2030. Valuation support comes from high dividend yields typical of tobacco stocks and defensive characteristics during economic uncertainty.

Thesis Status

The thesis remains intact and has strengthened marginally since the May 6 report. The competitive landscape in nicotine pouches has shifted favorably for BAT, with PMI's Zyn shipments declining 23.5% in Q1 due to inventory adjustments and regulatory delays, creating an opening for Velo to gain distribution and consumer trial. The measured pace of industry transition (PMI targeting 49% reduced-risk revenue by 2030 versus 66% goal) validates the thesis that combustible profitability will persist longer than bears anticipated. Consumer resilience in cigarette purchasing, evidenced by Altria's strong results despite economic pressures, supports cash flow stability assumptions. The +7.36% YTD performance suggests the market is recognizing these fundamental strengths.

Key Drivers

The primary driver is competitive repositioning in the nicotine pouch category. Philip Morris reduced full-year EPS guidance to $8.36-$8.51 from $8.38-$8.53, citing regulatory uncertainty on Zyn and intensifying competition from BAT's Velo. The FDA's delay in authorizing new Zyn versions through its fast-track scheme creates a window for BAT to expand Velo market share. Second, industry-wide smoke-free product revenue is growing but at a slower pace than initially projected, with PMI's smoke-free growth decelerating to 12.4% from 15% year-over-year, indicating the transition timeline extends further than aggressive forecasts suggested. Third, consumer behavior shows resilience in tobacco purchasing even amid economic pressure, with trade-down to discount brands rather than cessation. Fourth, geopolitical tensions are increasing transport and energy costs, which could pressure margins across the sector but may also create barriers to entry for smaller competitors.

Technical Analysis

BATS.L has established a clear uptrend since the April 14 low of £4,172, advancing through resistance at £4,300 and £4,400. The stock now trades at £4,524, testing the upper boundary of its recent range. The consistent positive momentum across 1-day (+3.31%), 5-day (+5.06%), 1-month (+3.98%), 6-month (+6.60%), and YTD (+7.36%) timeframes indicates strong buying pressure with no signs of exhaustion. The +2.14% gain since the May 6 report continues the recovery trajectory. Support has solidified at £4,300-£4,350, representing the previous resistance zone that has now flipped to support. Immediate resistance lies at £4,550-£4,600, which if breached would open potential for further gains toward £4,700. Volume patterns and the absence of significant pullbacks suggest institutional accumulation rather than retail-driven volatility.

Bull Case

• Competitive advantage in nicotine pouches as PMI faces regulatory delays: Philip Morris Zyn shipments declined 23.5% in Q1 with FDA delaying authorization of new versions due to concerns about youth access, creating market share opportunity for BAT's Velo brand to expand distribution and consumer trial during this regulatory vacuum.
• Extended profitability runway for combustible products: Industry leader PMI projects combustible cigarettes will still generate 51% of revenue by 2030, indicating the transition timeline is longer than bearish forecasts and supporting BAT's cash generation capacity from traditional products for years to come.
• Demonstrated pricing power and consumer resilience: Altria exceeded analyst expectations with higher-than-predicted cigarette sales despite economic pressure, with consumers trading down to discount brands rather than quitting, validating the sector's defensive characteristics and volume stability.
• Slowing competitive intensity in reduced-risk transition: PMI's smoke-free product revenue growth decelerated to 12.4% from 15% year-over-year, suggesting the disruption timeline is more gradual than feared and allowing BAT additional time to develop competitive offerings without existential pressure on the core business.
• Strong technical momentum with established support: The stock has recovered +8.44% from the April 14 low of £4,172, posting +7.36% YTD gains with consistent upward momentum across all timeframes (1d: +3.31%, 5d: +5.06%, 1m: +3.98%, 6m: +6.60%), indicating sustained institutional buying and support at £4,300-£4,350 levels.

Bear Case

• Structural disadvantage in reduced-risk product leadership: Philip Morris leads peers with 41.5% of revenue from smoke-free products as of 2025, positioning PMI to capture disproportionate value as the industry transitions while BAT plays catch-up with lower market share in the fastest-growing segment.
• Rising operational costs from geopolitical instability: PMI reduced full-year EPS guidance citing anticipated increases in transport and energy costs from regional geopolitical tensions, a headwind that affects all tobacco manufacturers including BAT and could compress margins if pricing power proves insufficient to offset inflation.
• Intensifying competition in nicotine pouches: Philip Morris explicitly cited intensifying competition from BAT's Velo as a factor in reducing guidance, indicating the category is becoming increasingly promotional and margin-dilutive as players fight for market share, potentially eroding profitability for all participants.
• Consumer trade-down pressure indicating economic stress: Altria reported increased demand for discount brands as rising gas prices prompt spending cuts, suggesting consumers are under financial pressure that could eventually lead to volume declines if economic conditions deteriorate further, particularly affecting premium brands where BAT has exposure.
• Regulatory risk remains elevated across the sector: FDA delayed Zyn authorization due to concerns about risks to new users including children, demonstrating that regulatory agencies remain focused on nicotine product access and youth protection, creating uncertainty for all reduced-risk products including BAT's portfolio and potentially limiting growth vectors.